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INTRODUCTION
MTP act can have an impact on reduction of maternal mortality and morbidity through 
safe abortion.
Where abortion is legal, it is generally reasonably safe, where it is illegal, complications 
are common, and about 78, 000 women die every year from these complications.
"Regardless of personal feelings about the ethics of interrupting pregnancy professionals 
have a duty to know the medical facts about abortion and share them with their patients".
Worldwide, about 46 million Women have abortions each year, and about half of these 
procedures  are  illegal  and  considered  "unsafe"
by the World Health Organisation. 
Unsafe abortion is a "Procedure for terminating an unwanted pregnancy either by person 
lacking the necessary skills or in an environment lacking  the minimal medical standards or 
both."
GLOBAL ABORTION SCENARIO 
Globally out of 210 million pregnancies, that occur each year, about 46 million (22%) 
end in induced abortion of which 20 million is estimated to be unsafe.
Majority of women are likely to have at least one abortion by the time they are 45 years. 
It is unfortunate and disheartening to note that in spite of liberalized abortion rules there is still 
one unsafe abortion for every 7 live birth. 
INDIAN ABORTION SCENARIO
3.1 lakh legal abortions are being performed every year with an abortion rate of 2.3%/ 
1000 pregnancy.
4.6 million illegal abortions are being performed every year with an illegal abortion rate 
of 130-200 / 1000 pregnancy.
MATERNAL MORTALITY
Due to legal abortion - 0.7/100, 000 
Due to criminal abortion - 500 / 100,000.
In  developing  countries,  risk  of  death  following  complication  of  unsafe  abortion 
procedure are much higher than when the abortion was performed professionally under safe 
condition. Complication of unsafe abortions may lead to sequel such as infertility, chronic PID, 
TO mass etc.  Hence safe and simple abortion procedures and techniques for  early-induced 
abortion are the need of the hour. When performed by trained health care providers with proper 
equipment, correct techniques and scrutinizing standard, abortion is one of the safest medical 
procedures.
Safe abortion services as provided by law should be;
 Easily available
 By well trained health care providers
 Regulation of health systems.
 Infrastructure including equipments and supplies
METHODS AVAILABLE FOR FIRST AND SECOND TRIMESTER MTP
FIRST TRIMESTER
1. Menstrual Regulation
2. Manual / Electrical vacuum aspiration
3. Dilatation and curettage.
4. Laminaria tent and prostaglandins for cervical dilatation.
5. Medical methods.
SECOND TRIMESTER
1. Extra amniotic instillation of ethacridine lactate 1% or 2%
2. Intra amniotic instillation of various agents.
3. Prostaglandins in various combination
4. Mechanical devices like laminaria tents, catheters
5. Aspirotomy
6. Hysterotomy
Many surgical methods of first trimester MTP have been associated with complications 
like
 Excessive Bleeding
 Uterine perforation
 Syncopal attacks
 Shock
 Infection
 Incompetence of os
 Cervical Stenosis
 Ashermann Syndrome
 Chronic Pelvic Inflammatory Disease
 Infertility.
Abortion in  -the  first  trimester  is  safe compared to  that  in  the second trimester  and 
medical methods are still safer than surgical techniques.
Medical methods are safe, efficient, simple and results usually in complete abortion of 
the  various  medical  methods.  Mifepristone  and  Misoprostol  have  largely  replaced  other 
procedures. Both Mifepristone and Misoprostol have been used singly in various doses and also 
in combination dosage schedule. There are many studies for both and each study claims its 
schedule to be superior and safer than others.
This study is taken to compare the efficacy, complications and complete abortion rate of 
mifepristone and misoprostol combination and misoprostol alone in first trimester MTP.
REVIEW OF LITERATURE
In India the MTP act was passed by parliament in 197land came into force on 1st April 
1972.
HISTORY
To reduce high maternal mortality associated with abortion, Govt of India set up
 Shantilal  Shah committee in 1964,  which recommended liberalization of abortion 
law to decrease MMR.
 Bill presented in Rajya Sabha, and Lok Sabha in 1969
 Act passed by parliament in August 1971, Implemented in April 1972 all over India
 Revised in 1975
 The act was amended in December 2002, and rules in June 2003.
I CONDITIONS    UNDER    WHICH    PREGNANCY    CAN    BE ERMINATED
(a)      Medical Grounds
Continuing of pregnancy might endanger the life of pregnant women.
Can  cause  grave  injury  to  physical  and  mental  health  like,  cardiac,  renal  diseases, 
diabetes, psychiatric illness.
 (b)      Eugenic Grounds
Risk of child being born with serious physical and mental handicap, hereditary disorder, 
viral infection.
(c) Humanitarian Grounds
Pregnancy due to rape or incest
(d) Social Grounds
Risk or injury to mental health of pregnant women
Failure of any contraceptive method
PROTECTIVE UMBRELLA OF MTP ACT
Even today voluntarily "Causing miscarriage to a woman with child other than in good 
faith for the purpose of saving her life" is a crime under section 312 of IPC. punishable with 
fine / imprisonment.
II       WHO CAN PERFORM MTP
Registered medical practitioner with obstetrics and gynaecology qualification.
Registered  medical  practitioner  with  postgraduate  qualification  in  obstetrics  and 
gynaecology.
Registered medical practitioner who has MTP certificate with training of 6 months in 
obstetrics and gynaecology.
III.      WHERE CAN BE PERFORMED?
(a)All government hospitals where facilities for MTP exists.
(b)At places recognized and approved by govt under the MTP act.
These rules in existence since 1972 were amended in 2002 and 2003 to incorporate some 
newer requirements to MTP and also to plug the lacunae and loopholes in the existing act.
HIGHLIGHTS OF NEW RULES ARE
Composition and tenure of District level committee
1.One member of District level committee shall be gynaecologist / surgeon/ anesthetist.
2.Other  members  from  the  local  medical  profession,  non-governmental  organization  and 
panchayat institution.
3.At least one member of the committee should be a woman.
The tenure of the committee would be for two calendar years and the tenure of the NGO 
member shall not be for more than two terms.
APPROVED PLACE
 A place for MTP up to 12 weeks - routine gynaecology clinic.
 A place for MTP up to 20 weeks - should have operation table to perform major surgical 
techniques.
FOR MEDICAL ABORTION
The clinic where an approved registered medical practitioner prescribes medical drugs 
does not need a approval.
EXPERIENCES
Up to 20 weeks
A practitioner should hold PG degree / diploma in obstetrics and gynaecology.
A  practitioner  who  has  completed  6  months  of  house  surgency  in  obstetrics  and 
gynaecology.
A  practitioner  who  has  at  least  one-year  experience  in  practice  of  obstetrics  and 
gynaecology.
Up to 12 Weeks
Practitioner who has assisted registered medical practitioner in the performance of 25 
cases of MTP, of which at least five has been performed independently in a hospital established 
or maintained by the Govt.
RCOG GUIDELINES FOR MEDICAL ABORTION
INFORMATION FOR WOMEN
Verbal advise and printed information has to be given to women 
Information to women about procedure 
Confidentially 
Informed consent
GESTATION AGE < 7 WEEKS
•Medical   abortion   using   mifepristone   -   misoprostol   is   an appropriate method
•Conventional suction termination should be avoided at gestation of < 7 weeks.
•Surgical   abortion  using   rigorous   protocol  may   also   be   an appropriate method for 
early termination of pregnancy.
RIGOROUS PROTOCOL CONSISTS OF
Pregnancy testing 
USG before procedure
Inspection of products of conception aspirated using magnification Follow up with  β 
HCG if gestational sac is not clearly seen.
RECOMMENDED REGIMENS FOR EARLY MEDICAL ABORTION
a. 200   mg   Mifepristone   orally   followed   by   prostaglandin   is adequate
b. Misoprostol,  a  PG  analogue  given  vaginally  is  a  cost  effective
alternative for all abortion procedures. E
200 mg of Mifepristone is as effective as 600 mg and evidence shows that Mifepristone 
given vaginally is a cost effective alternate to Gemeprost. (Crenin and Edwards)1
Combining Mifepristone with misoprostol  produce higher  rate  of  complete  abortion, 
than when misoprostol alone is used for this indication.
Complete abortion rate for mifepristone -  misoprostol  at  < 49 days was 96% and it 
decreases to 85% at > 57 days. The incomplete abortion rate increases from 2.9 to 10% and 
method failure rise from 1.1 to 7.2% with this regimen as gestational age increases.
The addition of more doses of misoprostol to the mifepristone-misoprostol regimen did 
increase the success rate and reduce both incomplete abortion rate and method failure rate. 
However incomplete abortion is less with vaginal misoprostol.
- Meta analysis. Kahn et al. 20002
COMPLICATION   AND    SEQULAE   BY   ROYAL   COLLEGE   OF OBSTETRICS 
AND GYNAECOLOGY
Hemorrhage Around 1.5 /1000 abortions
Rate is less in early abortion 
< 13 weeks    1.2 / 1000 abortions 
> 20 weeks 8.5 / 1000 abortions
Failed or continuation of pregnancy
Medical abortion 6.0 /1000 
Post abortion sequel
PID upto l0%
Rate is decreased when prophylactic antibiotics are used.
Future reproductive performance
No   proven   association   between   induced   abortion   and   subsequent preterm 
delivery or infertility.
Psychological Sequel
Only a small percentage of women experience a feeling of guilt. 
METHODS OF FIRST TRIMESTER ABORTION 
Medical methods
• Prostaglandins
• Methotrexate 
• Mifepristone (RU 486) 
• Mifepristone with PG analogues. 
[Ashok Et al 1998 and other studies]3'9
PROSTAGLANDINS
Blanchard  K  et  al  feels  that  misoprostol  when  used  alone  hold  promise  for  early 
termination of pregnancy /Blanchard K et al 2000J10
Various  studies  using  800  -  micro  gram  of  misoprostol  administered  
24 to 48 hrs apart shows success rates between 85% and 92% percentage.     
Ngai Sw et al., 200011
Tang12 and Ho tried 400 microgram of  misoprostol  up to  maximum of     5  doses 
sublingually for second trimester abortion with success rate of 100%.
The  Prostaglandins  other  than  misoprostol  like  Gemeprost  -  was  tried  in  various 
regimens.  (Kuldipsingh et al BJOG, Feb - 2003)13
Misoprostol is effective, less expensive than gemeprost and it does not need refrigeration 
- (RCOG 2000)14
METHOTREXATE
Methotrexate (both oral and intra muscular) combined with misoprostol have been under 
investigation  since  1993 with  complete  abortion  rates  similar  to  mifepristone regimens for 
pregnancies up to 49 days gestation.
{CreninMd, et. al 2000)15
50 mg/m body surface area of methotrexate followed by 800 microgram of misoprostol 
from day 3 to day 7, have shown to result in complete abortions in 83 to 96% of cases.
Crenin Md, 2000 and other studies)15-19
It was observed that abortion using methotrexate and misoprostol takes longer and may 
take up to 5 weeks in 20 to 30% of women.
Use of methotrexate for first trimester abortion is only of academic interest since WHO 
Toxicity panel recommended against methotrexate use due to its teratogenicity.
MIFEPRISTONE
Mifepristone an antiprogestin, currently being used extensively for first trimester MTP. 
It  acts  by  binding  with  progesterone  receptor  and  inhibits  the  action  of  progestin,  hence 
interfere with the continuation of pregnancy.
After confirming the eligibility to undergo medical abortion, 600 mg of mifepristone is 
administered orally or day 1.
On day  3,  the  patient  is  assessed  for  the  possibility  of  pregnancy expulsion,  which 
occurs in 2 to 5% of patients with mifepristone alone
MIFEPRISTONE WITH PG ANALOGUES
This is the most widely accepted method of early medical abortion.
Original protocol is 600 mg of mifepristone orally on day 1 followed by prostaglandin 
analogues on day 3. This has been associated with a success rate of 95%  -(Trusell elterson 
1989)7
In order to reduce the cost of 600 mg of mifepristone lower dose was tried.
Later it  was thought that 200 mg of mifepristone is as efficacious as     600 mg of 
mifepristone- (MC Kinky et. Al 1993)20
Then mifepristone in the  doses  of  200,400 & 600 were  tried followed by a vaginal 
gemeprost 48 hrs later. The success rate of above dosage regimens was found to be 93.8%, 94.1 
% and 94.3 % respectively. The overall continuation of pregnancy rate was 0.4% in all the 
regimens. (WHO task force on post ovulatory method of fertility, BMJ, 1993)21.
Two large trials with 2000 clients also confirmed the efficacy of 200 milligram of oral 
mifepristone with misoprostol vaginally (Ashok PW3, Schaff EA22, Contraception, 1999).
There was a randomized trial conducted in order to reduce the dose of mifepristone to 50 
mg orally followed 48 hrs later by gemeprost for early medical abortion. However the relative 
risk of failure with lower dose was calculated to be 1.6 times the higher dose. (WHO task force 
on postovulatory method for fertility regulation, BJOG, 2001).23
A large randomized study as to the most effective route of administration of misoprostol 
following  mifepristone  was  conducted  in  which  800  microgram  of  misoprostol  was 
administered vaginally or orally. The study found the vaginal route to be more efficacious with 
a complete abortion rate of 93%. The same after oral route was 78%. The failure rates were 
also higher in the oral route (7%) compared to the vaginal administration of misoprostol (1%) 
(ELRefacy, 1995)24
Many do not prefer Mifepristone and sulprostone combination as there is a high rate of 
MI follows sulprostone use. - Meta analysis, Kahn et at. 2000).2
The following combined regimen is recommended by RCOG for MTP with a pregnancy 
up to 9 completed weeks since LMP14 (2000).
200 mg Mifepristone followed by 36 - 48 hrs by 1.0 mg of vaginal gemeprost.
OR
800 mcg vaginal misoprostol
OR
400 mcg oral misoprostol up to 7 weeks.
All these were found to result in 98 % complete abortion
(Trusell - Elterson 1989)7
Parity and success rates of early medical abortion
Gestation Nulliparous % Parous %
< 7 weeks 98.6 96.2
7-8 weeks 98.3 93.1
8-9 weeks 96.4 91.0
> 9 weeks 73.3 83.0
1. In Nulliparous women gestational age had no influence on the outcome of pregnancy 
termination in early weeks.
2. However after 9 weeks of pregnancy, there was a significantly lower rate of complete 
abortion.
3. In parous women the complete abortion rate was lower after 7 weeks. 
(Bartley et at contraception 2000)25
Three regimens of Mifepristone   + misoprostol combination for   early medical abortion 
was advocated by Helene et al.
REGIMEN I REGIMEN II REGIMEN III
Ru 486 200 mg PO day 1
+
800 mcg miso PO day 3
+
400 mcg miso PO Bd 7 days
Ru 486 200 mg PO. day 1
+
800 mcg miso PV day 3
+
400 mcg miso PO Bd 7 days
Ru 486 200 mg PO day 1
+
800 mcg miso PV day 3
Complete abortion rate 92% Complete abortion rate 94.7 % Complete abortion rate 93.5 %
    Helene et al BJOG, Sept 200326
However studies from ICMR has shown 200 mg of mifepristone followed 36-48 hrs by 
400 meg of oral or vaginal misoprostol to be equally efficient with a Complete abortion rate of 
95% - 99% - ICMR27 1994.Aubency and Bauilieu281991.
On Going Trials
A large multicentric trial by WHO on mifepristone and misoprostol as an abortifacient in 
women with amenorrhoea up to  63 days is  being conducted.  The results  may reveal  more 
useful information on the efficacy of these drugs as a medical method of termination of early 
pregnancy.  
(WHO 1994)29
CONTRA   INDICATION   FOR  MIFEPRISTONE  -  MISOPROSTOL REGIMEN
1. Severe anemia
2. Adrenal failure
3. Medical disease that preclude use of misoprostol
4. Suspected ectopic pregnancy
5. Bleeding Disorders (WHO, 2000)30
SURGICAL METHODS OF FIRST TRIMESTER MTP
1. Menstrual regulator (MR)
2. Vacuum aspiration MVA / EVA
3. Suction evacuation / curettage
IMMEDIATE COMPLICATIONS OF SURGICAL METHODS
Excessive Bleeding       - (a)  Uterine atony
(b)  Retained products of conception
(c)  Uterine perforation
(d)   Cervical laceration
(e)   Post abortal syndrome
1.Syncopal attacks
2.Shock
3.Infection
DELAYED COMPLICATION
1. Incompetence of os
2. Cervical Stenosis
3. Ashermann Syndrome
4. Chronic Pelvic Inflammatory Disease
5. Infertility.
MIFEPRISTONE (RU - 486)
Discovered by French biochemist Dr.E.E. Baulieu working Roussel Ucluaf Mifepristone 
is  a  19  Nor  testosterone  derivative  which  is  an  antiprogestin.  Due  to  its  high  affinity  for 
progesterone receptor it competitively binds them.
The postulated mechanism of action is:
Stabilize receptor in non-DNA binding configuration
↓
Prevents gene transcription.
↓
Antagonistic action on Endometrium & trophoblast
↓
PG release
↓
Uterine contractions
↓
Conceptus detach from uterine wall
USES
I ABORTIFACIENT
 It acts on target cells of endometrium & decidua31
 Affects the pituitary gonadotrophic cells producing remarkable decrease in LH level 
which results in leuteolysis and shedding of endometrium.31
 Softens  and  ripens  the  cervix  and  produce  increased  release  of  myometrial 
prostaglandin resulting in expulsion of products of conception.32
 It also increases the sensitivity of uterus to exogenous prostaglandins.
 Anti glucocorticoid agent
 Weakly antiestrogenic34
Rodger,  Baird  B.J.O.G,  Baulieu  EF.  1989  Medline,  Henshaw  RC, 
TempletonAA, Johnstudd, 1993. Baird 1993.
II       AS A CONTRACEPTIVE
•Continuous  administration  of  the  drug  in  a  dose  of  20  mg from dayl  -  30  days  inhibits 
ovulation and delays menstruation.35
•Administration of 100 mg of mifepristone, 5 and 8 days after LH surge results in defective 
secretory endometrium.35
•Each month, administration of the drug in late luteal phase induces menstruation whether or 
not pregnant.34
•As a emergency contraceptive - 600 mg of mifepristone within 72 hrs of unprotected coitus 
has 100% success rate.36-37
(Wolf JP. Contr. - Baird DT. Contraception 1993, Van Sankon and Haspel 1987 / 
IPPF Med Bull 1988).
III.     CERVICAL DILATATION
To ripen the cervix prior to surgical method of MTP 
Reduce the induction - abortion interval in medical method
- Urquahart DL. Templeton AF Contraception 199038
OTHER SYNERGISTIC USES
 Endometriosis - Continuous use up to 3 months
      - Kettle LM - Fertility - Sterility39 /99/56
 Uterine leiomyoma  - 49% reduction of tumor size with 3-month use.
      - Howitz KB, Murphy Clinical Endocrin.40
 Meningioma - For unresectable humour
      - Grun Berg Neuro Surgery 199141
 Cushing's syndrome - Neiman LK et. al, J. Clinical Endo 198542
 For unruptured ectopic 
sac-
- Mifepristone     instilled    results    in
resolution of trophoblast.
 Glaucoma
 Viral infections
PHARMACOKINETICS
Following oral administration of mifepristone it rapidly gets absorbed with peak plasma 
level of 1.89 in 90 minutes.
98% bound to plasma proteins - albumin a! acid glycoprotein.
Following distribution phase, elimination of mifepristone is slow, the first 50% being 
eliminated in 12-17hrs followed by a more rapid elimination.
T 2 -18 hrs.
Metabolism via hepatic microsomal enzyme - iso enzyme cyp 3 A4
By 11 days after 600mg of drug 80% is excreted in faeces & 9% in urine.
Serum levels are undetectable after 11 days.
CONTRAINDICATIONS FOR MIFEPRISTONE
1.Confirmed or suspected ectopic pregnancy.
2.Undiagnosed adnexal mass
3.IUD in place
4.Hemorrhagic disorder or concurrent anticoagulant treatment
5.Inherited porphyrias
6.Chronic adrenal failure
7.H/o allergy to mifepristone or to other prostaglandins
8.Concurrent steroid treatment.
- WHO 200230
DRUG INTERACTIONS
Drugs that increase the serum level of mifepristone (through Cy P3 A4) :
Ketoconazole 
Itraconazole 
Erythromycin and 
Grape Juice
Drugs that decrease the scrum level of mifepristone
Rifampicin 
Dexamethasone
Phenytoin
Carbamazepine
Phenobarbitone.
Drug side effects
Abdominal pain
Uterine cramping
Diarrhea
Dizziness
Headache
Dyspepsia
Pelvic pain
Hypertension
Hashimoto's thyroiditis
MISOPROSTOL
It is a 11 alpha 16 dehydroxy 16 methyl 19 isoprost - 13E - en - coate. It is a synthetic 
prostaglandin structurally related to PGE!
Available as 100 mcg and 200-mcg tablet
Each tablet has
♦Hydrogenated castor oil
♦Hydroxy propyl methylcellulose.
♦Microcrystalline cellulose
♦Sodium starch glycolate
Misoprostol  inhibits  gastric  acid  secretion  &  promotes  bicarbonate  secretion.  It  is 
mucoprotective and is used in drug-induced gastric ulcer and also in duodenal ulcer.
Misoprostol  softens  the  cervix,  produce  uterine  contractions  without  exerting  any 
adverse effect on mother and fetus.
It is also used in second trimester abortion
No evidence of fetotoxic, teratogenic, carcinogenic effect in animal studies.
-  Oridi Im Br. J. Obst. gy.s 200043
PHARMACOKINETICS
•Rapidly absorbed orally
•Rapid deesterification to its acid which is responsible for clinical activity
•Reaches peak serum level in 15-30 minutes
•Half-life 20 - 40 minutes.
•Can be stored in ordinary temperature
•Vaginal application is better than oral route for MTP.
Dosage
1.First trimester MTP along with mifepristone 600 mg orally followed 48 hrs later by 800 meg 
of oral or vaginal misoprostol.
2.Second trimester along with mifepristone in   various doses in various regimens
Side effects
 Nausea
 Vomiting
 Headache
 Diarrhoea
 Hypotension
 Excessive Bleeding
 Abdominal / Uterine cramps
AIMS AND OBJECTIVES
 To assess the efficacy of mifepristone & misoprostol combination in first trimester 
abortion
 To compare this combination with vaginal misoprostol alone for first trimester MTP
 To compare the various parameters involved in MTP in both the methods & assess 
the most suitable method for first trimester MTP.
MATERIALS AND METHODS
The present study was carried out at Institute of Obstetrics and Gynaecology, Chennai - 
8 during 2007 - 2008.
The purpose of study is to compare the efficacy of mifepristone - vaginal misoprostol 
combination with vaginal misoprostol as a method of first trimester abortion.
Study design : Comparative Study
Study place : Institute  of  Obstetrics  and  Gynaecology, 
Chennai - 600 008.
Study Population : Patients requesting MTP who attended family 
planning Dept. IOG, Chennai.
Sample size : 100 (Random Allocation to either of groups)
50 - Mifepristone + Misoprostol Group
50 - Misoprostol Group
Year of Study : Jan 2007 - July 2008
INCLUSION CRITERIA
1.Confirmed pregnancy up to 9 weeks
2.Single intra uterine live gestation
3. No other medical or surgical contra indication for the procedure.
4. Contraceptive failure.
5. MTP for social & eugenic causes.
EXCLUSION CRITERIA
 Gestation age > 9 weeks
 Women smoke > 10 cigarettes / day
 Missed / incomplete / inevitable abortion
 Suspected ectopic pregnancy
 Any previous attempts at terminating the present pregnancy
 Pregnancies with IUD in situ.
METHODOLOGY
All these women were thoroughly investigated before MTP. The work up included ;
 Details of patient
 Investigations
 Examination of vital signs
 Abdominal and pelvic examination
 USG only on indication
 Counseling
Such of those women who were willing to adhere to the protocol were included for the 
study, provided they fulfilled the inclusion criteria.
DETAILS OF PATIENT
Name
Age Address
Socio economic status
Obstetric Formula
Menstrual history
Marital history
Obstetric history
Medical history
Surgical history
Examination of Patient
General Examination
Abdominal Examination
Bimanual pelvic examination
Routine Investigations like
Urine - Albumin
Sugar 
Hb%
ABO, Rh typing (if not done early) 
VDRL
HIV [with patient consent]
All these women are informed about the procedure. 
An informed consent was obtained from these selected women.
MIFEPRISTONE - MISOPROSTOL GROUP
The mifepristone - misoprostol protocol is an out patient procedure. Very few women 
who will not be in a position to reach the hospital in time, if there is bleeding, severe pain, 
vomiting etc. were admitted on humanitarian grounds.
Dosage schedule
Day 1 - 200mg of mifepristone was given orally. They were informed about 
symptoms and were asked to return to the hospital if the symptoms are severe.
Day 3 - 400 ug of misoprostol kept vaginally and observed for 4 hrs in OP dept 
90 % expelled within 4 hrs.
Such of these women who did not expel within 4-6 hrs after vaginal misoprostol were 
given the option of either going home and coming back on day 15 or admission in the hospital. 
Such of those women who preferred admission were admitted till the abortion is complete.
If evacuation is not complete even after 15 days it was considered as failure and the 
patients were offered other methods of termination.
MISOPROSTOL GROUP
50 patients were selected for vaginal misoprostol method of first trimester MTP.
Procedure
Patient was asked to empty the bladder and was asked to lie down in the dorsal position 
with knee semi flexed and hip abducted. After cleaning and draping, a Sim's speculum was 
introduced into vagina and posterior lip of cervix was caught with volsellum.
400 µg misoprostol was kept in posterior fornix and repeated 4 to 6 hrs apart depending 
on response (maximum 3 doses).
5 ml of distilled water instilled to dissolve the tablet the facilitate the absorption through 
mucosa.
Patient kept in the ward till expulsion is complete - Wherever necessary, check curettage 
was performed.
If  no  expulsion  occurred  after  20  -  24  hrs  it  is  considered  as  a  failure  and  other 
interventions offered.
Advised about the symptoms like, 
Nausea / vomiting / diarrhoea 
Abdominal Cramps 
Headache 
Bleeding
RESULTS
TABLE 1 : AGE
S.No. Age
Mifepristone + 
Misoprostol
Misoprostol
No. of 
Cases
%
No. of 
Cases
%
1. 18 - 20 4 8 3 6
2. 21 - 25 20 40 22 44
3. 26 - 30 18 36 15 30
4. > 30 8 16 10 20
Most of patients in both the groups were in age group of 20 - 30 years (75%).
In our study 16% of women from mifepristone misoprostol combination belongs to age 
group of above 30 and only 8% in the above combination group were below 20 years. The 
difference is of minimal significance (p = 0.001).
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TABLE 2: PARITY
S.No. Parity
Mifepristone + 
Misoprostol
Misoprostol
No. of 
Cases
%
No. of 
Cases
%
1. UMP 2 4 - 0
2. Primi 4 8 4 8
3. G2 36 72 38 76
4. G3 8 16 8 16
80% of women is both groups were parous whereas only 4% unmarried pregnancy noted 
in mifespristone + misoprostol group. None of them were unmarried in misoprostol group.
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TABLE 3 : ANALYSIS OF SOCIO ECONOMIC STATUS
S.No. Status
Mifepristone + 
Misoprostol
Misoprostol
No. of 
Cases
%
No. of 
Cases
%
1. Class I / II 2 4 0 0
2. Class III 8 16 6 12
3. Class IV/V 40 80 44 88
80%  of  women  in  both  groups  belong  to  Socioeconomic  
status of  IV / V. 
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TABLE 4 : GESTATIONAL AGE
S.No.
Gestational 
Age
Mifepristone + 
Misoprostol
Misoprostol
No. of 
Cases
%
No. of 
Cases
%
1. < 45 Days 30 60 18 36
2. 45 - 56 Days 15 30 28 56
3. > 56 Days 5 10 4 8
60% of women in mifepristone + misoprostol group where in the gestational age of < 45 
days whereas only 10% of women where in gestational age of above 56 days, on the contrary 
56% of women in misoprostol group belong to gestational age of 45 - 56 days. 
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TABLE 5 : INDUCTION ABORTION INTERVAL
Characters
Mifepristone + 
Misoprostol 
(in Hrs).
Misoprostol
Parity
UMP 5.00 -
G1 5.00 20
G2 4.00 18
G3 3.30 12.40
GA
< 45 3.30 - 4.00 18
45 - 56 4 - 4.30 18
> 56 days 6.00 24
When the induction abortion interval between mifepristone and misoprostol combination 
is compared with that of misoprostol alone it showed a p value of 0.000 thereby indicating that 
the reduced interval in the mifepristone - misoprostol group is significant. 
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TABLE 6 : ANALYSIS OF COMPLETE ABORTION
Sl.
No.
Characters
Mifepristone + Misoprostol Misoprostol
Incomplete 
Abortion
Method 
failure
Incomplete 
Abortion
Method 
failure
No. 
of 
Cases
No. 
of %
No. 
of 
Cases
No. 
of %
No. 
of 
Cases
No. 
of %
No. 
of 
Cases
No. 
of %
p 
value
1 Nullipara 0 0 0 0 0 0 0 0
2 Parous 2 4 1 2 24 48 5 10
0.000
Complete abortion rates in the two groups showed a significant variation in favour of 
mifepristone - misoprostol combination. 
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TABLE 7 : ANALYSIS OF SYMPTOMS
Sl.
No.
Symptoms
Mifepristone + 
Misoprostol
Misoprostol
No. of 
Cases
%
No. of 
Cases
%
1. Symptom Free 0 0 0 0
2. Abd / Ut.  Cramps 30 60 16 32
3. Excessive Bleeding 14 28 22 44
4. Vomiting 4 8 12 24
5. Dizziness 2 4 0 0
Comparing  the  significance  of  variables  in  the  symptoms,  both  groups  showed 
statistically significant incidence of side effects. However a larger study will be required to 
confirm the results ( p = 0.001).
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TABLE 8 : ANALYSIS OF POST ABORTIVE COMPLICATIONS
Sl.
No.
Conditions
Mifepristone + 
Misoprostol
Misoprostol
No. of 
Cases
%
No. of 
Cases
%
1. Vomiting 4 8 1 2
2. Persistent Bleeding 0 0 0 0
8%  of  women  in  mifepristone  +  misoprostol  had  vomiting  whereas  
2% of women in misoprostol had vomiting, No women had persistent bleeding in both the 
groups.
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DISCUSSION
This study was conducted at Institute of Obstetrics and Gynaecology,  Egmore, Chennai 
-600 008, during the period of 2007 - 2008. 100 Women were included in this study and the 
outcome analyzed using various parameters. The results were subjected to statistical analysis 
using the T - test - 2 tailed one sample test and chi-square test. 
Table - 1 : Age
Most of the patients in both the groups were in the age group of 20-30 years (75%). 
Women aged 35 years and above were not included in the original French study.
-WHO-199429
In our study 16% of women from Mifepristone - Misoprostol combination belongs to the 
age group of above 30 and only 8% in the above combination group were below 20 years. The 
difference is of minimal significance (p=0.001).
Table - 2 : Parity
Looking at the parity of women seeking MTP in the first trimester it was found that 
more than 80% of patient were second gravida, while 4% were unmarried. Parity is a major 
determinant of success rate in medical abortion.
In nulliparous women gestational age has no influence on the outcome of pregnancy 
termination in early weeks. However there was significantly lower rates of compete abortion in 
nulliparous women when  age of gestation was > 7 weeks.
Gestational Age In Days Complete Abortion
Nulliparous
< 49
50-56
57-63
>63
98.6%
98.3%
96.4%
11%
Whereas in parous women the rate of complete abortion was lower after 7 weeks.
Gestational Age Complete
In Days Abortion
Parous <49 96.2%
50-56 93.1%
57-63 91.8%
>63 10%
This is a retrospective analysis of 3161 cases by Bartley et al44. 
In the present study also 83% of women from both the group were parous.
Rational  for  this  varied  observation  in  different  gestational  age  still  remains 
unexplained. There is no variable significance in parity.
Table - 3 : Analysis of Socio Economic Status
Most of the women attending our hospital belongs to the marginalized group, Hence 
between 75 and 80% of women in both the groups were from socio economic class of IV and 
V. Socio economic status has no influence on the outcome.
Table - 4  : Gestational Age
Gestational age is the most important parameter that determines the successful outcome.
The influence of duration of pregnancy on successful MTP has been extensively studied. 
Kahn in  his  meta  analysis  finds  the  rate  of  complete  abortion  to  be  96% when period  of 
amenorrhoea is < 49 days, which declines to 85% when the gestational age is > 57 days.
Though initially medical abortion was used only up to 7 weeks, it has been extended to 
cover even those seeking abortion after 63 days. The rate of complete abortion in late MTPs 
was found to be 94.5% and the same increased to 95.7% when additional dose of 800 mcg of 
misoprostol was introduced vaginally.
-GolkEULacoln45
Spitz6 also  concur  with  other  studies  were  it  has  been  established  that  lesser  the 
gestational age more is the success rate.
Our study also compare well with these studies; complete abortion rate being 94% when 
the period of amenorrhoea is <49 days.
INDUCTION ABORTION INTERVAL
In  EL.Rafecy et  al24,  93% of  abortion occurred within 4 hrs  of  vaginal  misoprostol 
administration in mifepristone+ misoprostol and 78 % occurred with in 4 hrs if misoprostol was 
administered orally.
Present study also shows the induction abortion interval to be only 4 to 5 hrs following 
vaginal administration of misoprostol, which is similar to the results of EL. Rafecy et al24.
The induction abortion interval in this study when vaginal misoprostol alone was used 
for early MTP was found to be 23 to 24 hrs both in nulliparous and parous women. Moreover, 
the expulsion rate was more in parous women than nulliparous women. The study thus has 
findings similar to the study by Blanchard10, Velazco46, and Carboneil et al.18
In  our  study  none  of  the  women  were  Rh  negative.  Hence  there  was  no  need  for 
administering  anti  D  immunoglobulin.  If  the  client  is  Rh  negative,  
50 mcg of anti D immunoglobulin should be administered at the time of induction.
Thus the  combined regimen has more rate  of  complete  abortion with less  induction 
abortion interval than when misoprostol alone was used.
ANALYSIS OF COMPLETE ABORTION
The  present  study  had  2  cases  of  incomplete  abortion  in  mifepristone-  misoprostol 
group, the method failure rate was 2%, which indicates that additional methods like MVA were 
used in  these  patients.  These  results  were  similar  to  that  of  El  Refacy et  al  who reported 
complete abortion rate to be 95% in vaginal  instillation and 87% in oral  administration of 
Misoprostol  for first  trimester MTP. This again shows that complete abortion is more with 
vaginal  administration  than  oral  route.  Peyron  et  al24 in  a  1993  study  with  mifepristone-
misoprostol combination reported 96.9% complete abortion with 0.8% incomplete abortion.
When misoprostol was used alone for first trimester MTP, the complete abortion rate 
was found to be only 50% with high rate of incomplete abortion and method failure that made 
this regime unpopular.
Peyron et al4 has shown in a study that success rate of misoprostol when it is used alone 
is  85%  to  95%.  This  concludes  that  misoprostol  is  more  effective  when  it  is  used  in 
combination with mifepristone than when used alone for medical abortion.
All these studies including the present one reaffirms the fact that complete abortion rates 
are  more  in  early  pregnancy  either  with  mifepristone  +  misoprostol  or  misoprostol  alone. 
Similarly, a metalanalysis of 2000 patients reveal that the rate of incomplete abortion is more in 
parous women in misoprostol group.
This difference is statistically significant.
ANALYSIS OF SYMPTOMS
The symptoms were analyzed and the outcome of the study is interpreted as follows:
Vomiting was seen in 8% of our patients unlike the study by Cabeza et al47 in 1998 
where it was 15%. Though Spitz6 reports 100% bleeding in his study, only 28% of our patients 
had excessive bleeding. Both vomiting and bleeding were more when misoprostol alone was 
used for MTP (24 and 44% respectively).
Though blood transfusion was an option if bleeding is prolonged or excessive,, no such 
necessity arouse in our study. However blood loss was not a common side effect in the WHO, 
200030 study also.
60% of women from our study experienced pain that was similar to the rate of pain 
reported by Cabaze et al.47 Though pain was noted in many patients it was not very severe. Pain 
and bleeding increases with increasing gestational age in Henshaw et al.33
ANALYSIS OF POST ABORTIVE COMPLICATIONS
In  our  study  8%  of  women  from  Mifepristone  +  Misoprostol  group  had  vomiting 
whereas only one percent (2%) of women from Misoprostol group had vomiting. No patient 
had persistent Bleeding in both the groups.
SUMMARY
This is a comparative study of medical methods for first trimester  abortion conducted  at 
Institute of obstetrics and Gynaecology, Egmore, Chennai - 600 008.
Total no. of patients  - 100
No. of women who were given mifepristone & misoprostol combination - 50 
No. of misoprostol alone - 50
Following were the observations of this study.
1.Most of the patients were in the age group 21-30 and parous
2.4% of patients were unmarried who responded well for medical methods.
3. Almost all patients had various symptoms in both groups
4. Expulsion was complete in the mifepristone / misoprostol group with only 2 woman 
needing check curettage for confirmation of complete abortion. However in one women, 
there was no response and their pregnancy was terminated by MVA. On the other hand 
48% of women in the misoprostol alone group had to have curettage for completing the 
abortion process, and 10% of patients there was no response.  
5. Induction  abortion  time  is  less  in  patients  with  mifepristone  /  misoprostol  than 
misoprostol alone (4-5 hours vs 20-22 hrs. respectively).
6. None of the patients needed blood transfusion or volume expanders.
7. None  of  the  patients  had  delayed  bleeding  after  45  days.  On  an  average  Bleeding 
stopped within 25 days of expelling products. 
8. Misoprostol is less expensive and efficacious. However induction abortion interval is 
prolonged than mifepristone / misoprostol combination.
9. Though mifepristone is more expensive, the high complete abortion rate and expulsion 
within 4-5 hrs of misoprostol administration makes it a preferred method where cost is 
not a restraining factor.
CONCLUSION
1.Mifepristone misoprostol combination is an effective out patient procedure for early MTP 
and is ideal for home management.
2.Complete abortion rate is high with this combination.
3.Similarly the induction abortion interval with this method is also less.
4.Other associated complications are less.
The  only  confounding  factor  is  the  cost  involved  which  is  about  20  times  that  of 
misoprostol alone.
This makes the routine use of mifepristone misoprostol combination for first trimester 
abortion an effective option where cost is not a consideration or in situations where an early 
abortion is required.

BIBLIOGRAPHY
 Crenin MD, Edwards  J.Early abortion surgical  and medical  options current problem 
obstet gynaecology fertil 1997; 20:6-32
 Kahn JG,  Becker  BJ,  Maclsaa  L,  Amory  JK,  Neuhas  J,  Olkin  I,  Creinin  MD.  The 
efficacy of medical abortion : a meta - analysis. Contraception; 61 (1): 29-40, January 
2000.
 Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical 
abortion: a report of 2000 consecutive cases. Hum Repord; 13:2962-5, 1998.
 Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik P et al. Early termination 
of  pregnancy  with  mifepristone  (RU  486)  and  the  orally  active  prostaglandin 
misoprostol. N Engl J Med; 328: 1509-13, 1993.
 Schaff  EA,  Eisinger  SH,  Stadalius  LS,  Franks  P,  Gore  BZ,  Boppema S.  Low dose 
mifepristone 200mg and vaginal misoprostol for abortion. Contraception; 59:1-6, 1999.
 Spitz  IM,  Bardin  CW,  Benton  L,  Robbins  A.  Early  pregnancy  termination  with 
mifepristone and misoprostol in the United States.      N Engl J Med; 338:1241-5,1998.
 Trussell  J  and  Ellertson  C.  (1998)  Estimating  the  efficacy  of  medical  abortion. 
Conception 60:119 - 135.
 Urqutart DR, Templeton AA, Shinewi F, Chapman M, Hawkins K, Mcgarry J, Rodger 
M, Barid DT et al. (1997) The efficacy and tolerance of mifepristone and prostaglandin 
in termination of pregnancy of less than 63 days gestation; UK multicentre study - final 
results. Contraception 5:1-5.
 Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Ziao B, Gu S, Du Mk, Krishna UR, Eschen 
A and Ellertson C. (1997) Safety,  efficacy,  and acceptability  of medical  abortion in 
China, Cuba and India : a comparative trial of mifepristone - misoprostol versus surgical 
abortion. American Journal of Obstetrics and Gynecology 176:431-437.
 Blanchard K, Winikoff B, Coyaji K, Nguyan TN. Misoprostol alone - a new method of 
medical  abortion  ?  J  Am  Med  Women's  Assoc;  55  
(3 Suppl): 189-90, 2000.
 Ngai SW, Tang OS, Chen YM, Ho PC. Vaginal misoprostol alone for medical abortion 
up to 9 weeks of gestation: efficacy accountability. AnnReprod; 15: 1159-62, May 2000.
 Tang OS, Ho PC, Pilots study on the use of sublingual misoprostol for medical abortion. 
Contraception 2001; 64:315-7A
 Kuldip  Singh  et  al  prostaglandins  in  MTP  BJOG,  Feb  2003;  110:
175-180.
 RCOG - Royal College of Obstetricians and Gynaecologists. (2000). The care of women 
requesting induced abortion. Evidence - based guideline No.7. London, RCOG Press.
 Crenin MD, Pymar HC, Medical abortion alternative to mifepristone J.Am Med women 
association 53 (3 suppl): 127-32, 2000.
 Ozeren M, Bilekli C, Aydemir V, Bozkaya H. Methotrexate and misoprostol used alone 
or in combination for early abortion. Contraception; 59(6)-: 389-94, June 1999.
 Wiebe  ER.  Comparing  abortion  induced  with  methotrexate  and  misoprostol  to 
methotrexate alone. Contraception; 59 (1) : 7-10, January 1999.
 Carbonell Esteve JL, Varela L, Velazco A, Tanda R, Sanchez C. 25mg or 50 mg of oral 
methotrexate  followed  by  vaginal  misoprostol  7  days  after  for  early  abortion:  a 
randomized  trial.  Gynecol  Obstet  Invest;  
47 (3): 182-7,1999.
 Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. N Engl J 
Med; 333 (9) : 537-40, August 31, 1995.
 McKinley C, Thong KJ and Baird DT. (1993) The effect of dose of mifepristone and 
gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human 
Reproduction 8:1502-1505.
 World  Health  Organization  Task  Force  on  Post  -  ovulatory  Methods  for  Fertility 
Regulation.  (1993)  Termination  of  pregnancy  with  reduced  doses  of  mifepristone. 
British Medical Journal 307:532-537.
 Schaff EA, Eisinger SH, Stadalms LS, Franks P, Gore BZ and Popperna S. (1999) Low - 
dose mifepristone 200mg and vaginal misoprostol for abortion. Contraception 59:1-6.
 World  Health  Organization  Task  Force  on  Post-ovulatory  Methods  for  Fertility 
Regulation.  Lowering the dose of Mifepristone and gemeprost  for early abortion :  a 
randomized  controlled  trial.  BJOG;  108(7)
 738-42, July 2001.
 El-Refaey H, Rajasekar D, Abdalla M, Calder L and Templeton A. (1995) Induction of 
abortion  with  mifepristone  (RU$*A)  and  oral  or  vaginal  misoprostol.  New England 
Journal of Medicine 382:983-987.
 Bartely J. Tong S, Everington D. Baird DT. Contraception 2000; 62: 297-303.
1.Helene mifepristone - misoprostol use early abortion BJOG, Sep 2003; 110:808-818.
2.ICMR, Task Force on Amti-implanatation /  Menstrual regualting Agents,  Study Protocol, 
New Delhi, 1994.
3.Aubeny B. Baulieu EE. Academic des Sciences Paris 1991 : 312:539.
4.WHO Abortion, 2nd edn, Geneva; World Health Organization, 1994.
5.World Health Organization (2000b) Improving access to quality care in family planning : 
medical eligibility criteria for contraceptive methods. Second edition. Geneva, World Health 
Organization, (WHO/00.02).
31.Baulieu  EE.  Contragestation  and  other  clinical  application  of   mifepristone  and 
antiprogestinat the receptor gene. 1989, (145 : 1351- 1357) Medline.
26.Rodger  MW,  Baird  DTS Pretreatment  with  mifepristone  reduces  interval  between 
prostaglandin  and  expulsion  second  trimester  abortion  
Dr BJOG ob gynec. 1990; 97, 41-45 (medline)
27.Henshaw RC, Templeton AA, Antiprogesterone. Progress in obstetrics and gyn vol.10 Ed. 
John Studd pp 259-279, Churchill livingston 1993.
28.Baird  DT.  In  :  Drife  JO,  Baird  DT  (des)  .  Contraceptive  Research  for  today  and  the 
livingsotne, 1993 : 73.
29.Wolf  JP,  Ulmann  A,  Baulieu  EE,  Contraception  potency  of  mifepristone  by  Ovulation 
inhibition and Suppression of Pituitary Gonodotrophin secretion in vitro contraception 1989; 
40:185-193 (medline)
30.Van Sankon MR, Haspel AA, contraception 1987a; 35:423.
31.IPPF. Inter plan parent med Bull 1994; 28(6): 1.
32.Urquahat DT. Templeton A A. Mifepristone for cervical priming for surgical method of 
abortion in last first trimester contraception 1990; 42: (191-199). medline.
32.Kettel  LM,  Murphy  AA,  Ulmann  AS.  Yen  SS,  endocrinal  response  to  long  term 
administration of the antiprogestine. Mifepristone regular endo trimester fertility contraception 
1991, 56: 402-407 (medline)
33.Howitz  KB,   Murphy  AA,  Kettel  LM,  Regression  of  uterine  leiomyoma a  response  to 
antiprogestin   on clinical endocrine metabolism   1993; 76:513-517 (Abstract)
6. Grunberg  SM.  Weizz  MA,  treatment  of  unresectable  meningioma  with 
antiprogestin mifepristone. Neuro surgery 1991 : 74:861-866 (medline)
7. Nieman LK,. Successful treatment of cushings syndrome with glucocorticoids, 
mifepristone, J.clinical endocrine metabolism 1985; 61:536-50 (abstract)
8. Orioli IM, Catilla EE, Epidemiological assessment of misoprostol teratogeniciry. 
BJOG; 107(4): 519-23, April 2000.
9. Gouk EV, Lincoln K, Khair A, Haslock J, Knight J, Cruickshank DJ. Medical 
tremination  of  pregnancy  at  63  to  83  days  gestation.  Br  J  obstet  Gynaecol; 
106:535-39, 1999.
10. Velozco A,  Varela  L,  Tanda R,  Sanchez C,  Barambio S,  Chani  S,  Valero  F, 
Aragon  S,  Mari  J,  Carbonell  JL.  Misoprostol  for  abortion  up  to  9  weeks  in 
adolescents. Eur J contracept reprod health care; 5(4) : 227-33, December 2000.
11. Cabezas  E.  Medical  versus  surgical  abortion.  Int  J  Gynaecol  Obstet;  
63 suppl LS141-6, December 1998.
